Why is a second opinion important in mesothelioma?
Mesothelioma is a rare disease, and there has not been a sufficient number of multi-institutional clinical trials to reach a consensus on how to treat this disease. Today, surgeons and medical oncologists at different institutions often disagree on the best operation or the best chemotherapy drug to use for a given patient. Patients who see and listen to only a single oncologic group at a single institution are automatically under some degree of coercion to follow its recommendations, because they don't know who else to trust.
Patients who solicit opinions from several different groups are better informed and strongly empowered; they can choose between alternatives and decide how they will be treated.